company background image
ADXN logo

Addex Therapeutics SWX:ADXN Stock Report

Last Price

CHF 0.063

Market Cap

CHF 6.0m

7D

-0.6%

1Y

-21.5%

Updated

30 Jan, 2025

Data

Company Financials +

Addex Therapeutics Ltd

SWX:ADXN Stock Report

Market Cap: CHF 6.0m

ADXN Stock Overview

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. More details

ADXN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap (CHF6M)

Makes less than USD$1m in revenue (CHF592K)

Highly volatile share price over the past 3 months compared to the Swiss market

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Addex Therapeutics Ltd Competitors

Newron Pharmaceuticals

SWX:NWRN

CHF 189.6m

Spexis

SWX:SPEX

CHF 3.0m

ANG Lifesciences India

BSE:540694

₹505.5m

Y.B Urban Renewal - Residential Development

TASE:YBRD

₪24.5m

Price History & Performance

Summary of share price highs, lows and changes for Addex Therapeutics
Historical stock prices
Current Share PriceCHF 0.063
52 Week HighCHF 0.26
52 Week LowCHF 0.05
Beta1.89
1 Month Change9.79%
3 Month Change-24.52%
1 Year Change-21.50%
3 Year Change-92.99%
5 Year Change-96.83%
Change since IPO-99.91%

Recent News & Updates

Recent updates

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Mar 03
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

May 11
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Nov 23
Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Shareholder Returns

ADXNCH PharmaceuticalsCH Market
7D-0.6%3.2%2.1%
1Y-21.5%10.3%8.6%

Return vs Industry: ADXN underperformed the Swiss Pharmaceuticals industry which returned 10.3% over the past year.

Return vs Market: ADXN underperformed the Swiss Market which returned 8.6% over the past year.

Price Volatility

Is ADXN's price volatile compared to industry and market?
ADXN volatility
ADXN Average Weekly Movement12.6%
Pharmaceuticals Industry Average Movement3.0%
Market Average Movement3.5%
10% most volatile stocks in CH Market8.2%
10% least volatile stocks in CH Market1.7%

Stable Share Price: ADXN's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: ADXN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
200223Tim Dyerwww.addextherapeutics.com

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.

Addex Therapeutics Ltd Fundamentals Summary

How do Addex Therapeutics's earnings and revenue compare to its market cap?
ADXN fundamental statistics
Market capCHF 5.96m
Earnings (TTM)-CHF 12.67m
Revenue (TTM)CHF 592.36k

10.4x

P/S Ratio

-0.5x

P/E Ratio

Is ADXN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADXN income statement (TTM)
RevenueCHF 592.36k
Cost of RevenueCHF 6.69m
Gross Profit-CHF 6.09m
Other ExpensesCHF 6.58m
Earnings-CHF 12.67m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 24, 2025

Earnings per share (EPS)-0.13
Gross Margin-1,028.84%
Net Profit Margin-2,139.51%
Debt/Equity Ratio0%

How did ADXN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 19:12
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Addex Therapeutics Ltd is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas MeyerBaader Helvea Equity Research
Leonildo DelgadoBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research